The company's capital structure is under significant strain, evidenced by a $2.3 billion equity deficit and a total debt load that has climbed to $3.4 billion as of 2026Q1.
| Total Current Assets | 1.18B | 753.68M | 720.69M | 477.59M | 548.85M | 888.86M | 642.82M | 568.62M | 445.22M | 97.13M |
| Cash & Short-Term Investments | 940.19M | 587.48M | 681.1M | 434.88M | 471.92M | 836.66M | 607.09M | 545.99M | 436.09M | 92M |
| Cash Only | 879.89M | 570.12M | 681.1M | 375.94M | 376.69M | 393.77M | 356.08M | 363.77M | 436.09M | 92M |
| Short-Term Investments | 60.3M | 17.36M | 0 | 58.95M | 95.23M | 442.89M | 251.01M | 182.22M | 0 | 0 |
| Accounts Receivable | 205.23M | 139.44M | 4.72M | 1.75M | 17.08M | 19.75M | 0 | 2.85M | 0 | 0 |
| Days Sales Outstanding | 84.66 | 101.37 | 7.77 | 68.7 | 80.28 | 103.4 | - | 25.6 | - | - |
| Inventory | 32.98M | 26.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 259.48 | 345.38 | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 3.83M | 27.65M | 37.93M | 177K | 139K | 0 | 0 | 889K |
| Total Non-Current Assets | 49.53M | 41.59M | 198.65M | 68.79M | 74.18M | 123.93M | 60.76M | 63.06M | 19.72M | 913K |
| Property, Plant & Equipment | 22.17M | 13.52M | 12.78M | 19.84M | 25.25M | 45.97M | 36.83M | 5.63M | 1.57M | 440K |
| Fixed Asset Turnover | 38.43x | 37.15x | 17.37x | 0.47x | 3.08x | 1.52x | 0.22x | 7.21x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 27.36M | 28.08M | 23.93M | 26.32M | 28.71M | 44.93M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 346.42M | 81.44M | 143.75M | 0 | 0 | 0 | 0 | 31.14M | 17.05M | 381K |
| Other Non-Current Assets | -63.11M | -81.44M | 18.2M | 22.63M | 20.22M | 33.03M | 23.93M | 26.29M | 1.09M | 92K |
| Total Assets | 1.37B | 936.02M | 919.34M | 546.38M | 623.04M | 1.01B | 703.59M | 631.68M | 464.94M | 98.04M |
| Asset Turnover | 0.53x | 0.54x | 0.24x | 0.02x | 0.12x | 0.07x | 0.01x | 0.06x | - | - |
| Asset Growth % | 143.42% | 1.82% | 68.26% | -12.3% | -38.48% | 43.95% | 11.38% | 35.86% | 374.22% | - |
| Total Current Liabilities | 816.37M | 287.97M | 154.4M | 143.84M | 121.43M | 135.07M | 95.65M | 60.38M | 32.58M | 8.55M |
| Accounts Payable | 29.06M | 36.23M | 9.62M | 10.65M | 11.56M | 11.88M | 8.95M | 8.85M | 13.51M | 1.89M |
| Days Payables Outstanding | 278.67 | 467.7 | 905.25 | 1.59K | 1.23K | 1.39K | - | 1.29K | - | 2.65K |
| Short-Term Debt | 573.41M | 17.41M | 0 | 0 | 0 | 0 | 1.46M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 57.79M | 20.27M | 0 | 6.1M | 8.16M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 196.01M | 214.06M | 16.2M | 65.59M | 31.26M | 37.04M | 9.55M | 25.39M | 4.01M | 997K |
| Current Ratio | 1.44x | 2.62x | 4.67x | 3.32x | 4.52x | 6.58x | 6.72x | 9.42x | 13.67x | 11.36x |
| Quick Ratio | 1.40x | 2.52x | 4.67x | 3.32x | 4.52x | 6.58x | 6.72x | 9.42x | 13.67x | 11.36x |
| Cash Conversion Cycle | 65.46 | -20.95 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.82B | 2.72B | 2.22B | 1.75B | 1.75B | 1.74B | 500.05M | 95.32M | 533.87M | 144.18M |
| Long-Term Debt | 2.8B | 2.71B | 1.72B | 1.73B | 1.71B | 1.7B | 475.86M | 91.79M | 54.51M | 143.87M |
| Capital Lease Obligations | 25.48M | 3.81M | 4.7M | 8.98M | 12.27M | 17.43M | 14.68M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 229K | 244K | 496.47M | 9.36M | 26.64M | 22.07M | 9.52M | 3.53M | 479.36M | 312K |
| Total Liabilities | 3.64B | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B | 595.7M | 155.7M | 566.44M | 152.73M |
| Total Debt | 3.38B | 2.73B | 1.73B | 1.74B | 1.72B | 1.73B | 495.79M | 91.79M | 54.51M | 143.87M |
| Net Debt | 2.5B | 2.16B | 1.05B | 1.36B | 1.35B | 1.33B | 139.71M | -271.98M | -381.58M | 51.87M |
| Debt / Equity | -1.49x | - | - | - | - | - | 4.60x | 0.19x | - | - |
| Debt / EBITDA | -6.03x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -4.46x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -5.34x | -12.84x | -4.46x | -7.04x | -5.03x | -11.54x | -12.79x | -31.92x | -72.11x | -3370.69x |
| Total Equity | -2.27B | -2.08B | -1.46B | -1.34B | -1.24B | -865.58M | 107.89M | 475.98M | -101.5M | -54.69M |
| Equity Growth % | -203.18% | -42.5% | -8.57% | -7.84% | -43.83% | -902.31% | -77.33% | 568.93% | -85.61% | - |
| Book Value per Share | -11.65 | -10.53 | -7.83 | -8.25 | -8.44 | -6.00 | 0.91 | 4.53 | -1.10 | -0.59 |
| Total Shareholders' Equity | -2.27B | -2.08B | -1.47B | -1.35B | -1.25B | -870.41M | 57.91M | 408.45M | -163.99M | -58.02M |
| Common Stock | 204K | 202K | 196K | 181K | 157K | 154K | 125K | 124K | 6.59M | 3.41M |
| Retained Earnings | -3.99B | -3.82B | -3.1B | -2.56B | -1.92B | -1.44B | -888.75M | -440.03M | -170.58M | -61.43M |
| Treasury Stock | -405.78M | -323.28M | -275M | -275M | -275M | -275M | -75M | 0 | 0 | 0 |
| Accumulated OCI | -8K | 12K | 8K | 31K | -328K | -132K | 192K | 254K | -231K | -27K |
| Minority Interest | -951K | -570K | 10.29M | 11.72M | 9.69M | 4.83M | 49.98M | 67.52M | 62.48M | 3.33M |
High leverage and dilution
According to recent balance sheet data, BridgeBio's equity position has deteriorated to a deficit of $2.3 billion in 2026Q1, reflecting a persistent trend of capital erosion as the company continues to fund its expansive clinical pipeline through significant debt accumulation and ongoing operational losses.
The widening equity deficit suggests that the company's reliance on external financing is outpacing its ability to generate internal value, effectively shifting the burden of risk onto the capital structure. Investors should monitor whether the transition to commercial-stage operations can arrest this downward trajectory before the balance sheet reaches a critical inflection point.
As reported in financial statements, BridgeBio's total debt has surged to $3.4 billion as of 2026Q1, indicating that the firm is utilizing aggressive debt-based financing to sustain its hub-and-spoke development model in the absence of consistent, self-funding product revenue streams.
This high level of indebtedness relative to the company's current asset base suggests a precarious reliance on debt markets, which may limit future strategic flexibility. The concentration of liabilities warrants further investigation into the maturity profile and potential refinancing risks that could emerge if clinical milestones are delayed.
Based on reported figures, BridgeBio held $879.9 million in cash as of 2026Q1, providing a current ratio of 1.44, which suggests a tightening liquidity buffer as the company scales its commercial infrastructure ahead of potential product launches.
While the current ratio remains above parity, the rapid consumption of cash reserves to support R&D and commercialization efforts implies that the company may face recurring liquidity pressure. The reliance on milestone-driven cash inflows makes the liquidity position highly sensitive to the timing of regulatory and clinical outcomes.
Analysis of the consolidated balance sheet reveals that the $3.6 billion in total liabilities may obscure specific risks associated with non-controlling interests and contingent consideration, which are inherent to the company's decentralized hub-and-spoke organizational structure.
These off-balance-sheet-like obligations and minority stakes in subsidiaries may complicate the true assessment of shareholder equity and potential future cash outflows. Investors should be cautious that the headline debt figures might not fully capture the complexity of the firm's total financial commitments to its various clinical programs.
Quick answers to the most common questions about buying BBIO stock.
As of 2025, BridgeBio Pharma, Inc. (BBIO) had total assets of $936.0M including $753.7M in current assets.
BridgeBio Pharma, Inc. (BBIO) carries total debt of $2.73B, offset by $587.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
BridgeBio Pharma, Inc. (BBIO) has total shareholders' equity (book value) of $-2076.6M ($-10.53 book value per share). Book value represents the net worth of the company belonging to common stock holders.
BridgeBio Pharma, Inc. (BBIO) reported a current ratio of 2.62x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.